Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement

Transpl Int. 2023 Sep 29:36:11729. doi: 10.3389/ti.2023.11729. eCollection 2023.

Abstract

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines' Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.

Keywords: IBD; PSC; immunosuppression; liver transplantation; retransplantation.

MeSH terms

  • Cholangitis, Sclerosing* / complications
  • Cholangitis, Sclerosing* / surgery
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / surgery
  • Liver Transplantation*
  • Risk Factors

Substances

  • Immunosuppressive Agents

Grants and funding

All costs related to taskforce and workgroup meetings were covered by ESOT, without external funding.